This webinar addressed the risks and risk management tools for wound care practitioners and manufacturers related to federal and state health care fraud enforcement under the federal False Claims Acts, including its “whistleblower” provisions.
Marcia Nusgart, R.Ph., of the Alliance of Wound Care Stakeholders, moderated a panel discussion by attorneys George B. Breen, David E. Matyas, and Lynn Shapiro Snyder of Epstein Becker Green.
Why Should You Care?
The U.S. Department of Justice (DOJ) announced that it is stepping up its use of the False Claims Act to investigate criminal activity in health care. Previously, most activity was limited to civil courts and involved only monetary recoupment. However, the DOJ is now often pursuing parallel criminal and civil investigations of health care fraud.
Who Should Care: Clinicians, Corporate Officers, Administrators and Manufacturers
On September 9, 2015, DOJ issued new guidance on individual accountability for corporate wrongdoing. In a memorandum by Deputy Attorney General Sally Q. Yates (the “Yates Memorandum”), the DOJ provides six specific accountability criteria designed to guide fraud enforcement investigations. You need to know these criteria, because they may call for a shift in how you or your customers carry out your personal compliance obligations.
Learning Objectives
This webinar provided insight into expanding government investigations and offered ways to enhance your compliance efforts including:
- High risk health care fraud issues
- How to manage a ‘touch’ by the government enforcement players such as the receipt of a subpoena, and
- The current enforcement climate
